Eurofins Viracor Launches New Quantitative PCR Assay for Chagas Disease (T. cruzi) Diagnosis
LENEXA, Kan., Jan. 15, 2025 /PRNewswire/ -- Eurofins Viracor, LLC a leading provider of specialty diagnostic testing, and part of the global network of Eurofins companies, is pleased to announce the launch of an innovative quantitative PCR assay for the detection of Trypanosoma cruzi (T. cruzi), the parasitic cause of Chagas disease.
The Chagas (T. cruzi) qPCR test is a crucial tool for the accurate detection of Trypanosoma cruzi infection, a disease that often goes undiagnosed due to its asymptomatic nature in its early stages.
With an estimated 300,000 people infected with Trypanosoma cruzi in the United States1 this test is vital for identifying individuals at risk—particularly transplant recipients, who may face potential transmission from donor organs, or immunocompromised patients, who are at risk of reactivation of a prior infection. Many infection cases have the potential of going undiagnosed due to the limitations of traditional diagnostic methods. Eurofins Viracor's new assay addresses this critical gap by providing:
- A well-established preanalytical process designed to reduce testing delays and minimize instances of testing not performed (TNP).
- A sensitive, quantitative PCR assay with rapid turnaround times, delivering results within 48 hours of receipt of sample.
The launch of a quantitative PCR assay for Chagas disease underscores Eurofins Viracor's commitment to improving diagnostic solutions for underserved conditions. The company believes that, with this assay, healthcare providers can gain a powerful tool to better diagnose, monitor, and manage Chagas disease, ultimately improving patient outcomes.
The new assay is now available for order from Eurofins Viracor. For more information, visit 33432 - Chagas (T.cruzi) qPCR | Clinical | Eurofins-Viracor or contact Client Services at (800) 305-5198.
Notes to Editors:
About Eurofins Viracor
With over 30 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Eurofins Viracor is committed to helping medical professionals, transplant teams and reference laboratories get results faster, when it matters most. Viracor is passionate about delivering value to its clients by providing timely, actionable information, never losing sight of the connection between the testing it performs and the patients it ultimately serves. Viracor is a 100 percent subsidiary of Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit https://www.eurofins-viracor.com/.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With ca. 62,000 staff across a network of more than 900 laboratories in over 1,000 companies in 62 countries, Eurofins offers a portfolio of over 200,000 analytical methods.
Eurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.
1 Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009;49:655–681. doi: 10.1086/605091
View original content to download multimedia:https://www.prnewswire.com/news-releases/eurofins-viracor-launches-new-quantitative-pcr-assay-for-chagas-disease-t-cruzi-diagnosis-302349537.html
SOURCE Eurofins Viracor, Inc.